Latency and Early Neonatal Provision of Antiretroviral Drugs Clinical Trial (LEOPARD)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT02431975|
Recruitment Status : Completed
First Posted : May 1, 2015
Last Update Posted : August 4, 2020
- Study Details
- Tabular View
- No Results Posted
- How to Read a Study Record
The investigators propose a non-randomized clinical trial of 60 HIV-infected infants identified within 48 hours of birth and their mothers to investigate the consequences of very early ART on the establishment and maintenance of the viral reservoir.
The first phase (early ART initiation within 48 hours of birth) will examine the trajectory i.e. changes over time of the viral reservoir and detection of HIV-specific antibody responses in infants testing HIV-positive within 48 hours of birth and initiating early ART.
Secondary pathogenesis aims will test whether markers of neonatal immune quiescence are associated with the extent of seeding and rate of decline of the viral reservoir when ART is started at a young age and investigate whether markers in infant stool samples can be used as a non-invasive method of defining relevant immune and HIV-specific parameters associated with viral reservoir size.
The investigators hypothesize that developmental characteristics of newborn immunity may make this period the optimal time to begin ART and influence the seeding of the viral reservoir.
|Condition or disease||Intervention/treatment||Phase|
|HIV||Drug: Nevirapine Drug: Zidovudine Drug: Lamivudine Drug: LPV/r||Phase 4|
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||73 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||Latency and Early Neonatal Provision of Antiretroviral Drugs Clinical Trial|
|Actual Study Start Date :||August 2015|
|Actual Primary Completion Date :||April 30, 2020|
|Actual Study Completion Date :||April 30, 2020|
Experimental: Early ART
All infants enrolled in the trial, regardless of maternal PMTCT regimen, will be initiated on a triple ARV regimen consisting of nevirapine (NVP), zidovudine (ZDV) and lamivudine (3TC) presumptively based on the initial positive result. This regimen will be continued to 42 weeks post menstrual age (PMA). At this time, infants will be switched to LPV/r, ZDV and 3TC to be continued to 104 weeks or longer unless otherwise preferred by the treating clinician or if any clinical or laboratory contraindications are identified.
Standard medication used to treat and prevent HIV/AIDS, specifically HIV-1. It is generally recommended for use with other antiretroviral medication.
The initial dose of NVP will be 6 mg per kg per dose orally twice daily until 42 weeks gestational age (2 weeks of age for infants born at term) which is the dosing selected by the NIH International Maternal, Pediatric, Adolescent AIDS Clinical Trials (IMPAACT) Network.
An antiretroviral medication used to prevent and treat HIV/AIDS. It is generally recommended for use with other antiretroviral.
ZDV will be dosed as per standard guideline and routine practices.
An antiretroviral medication used to prevent and treat HIV/AIDS. It is effective against both HIV-1 and HIV-2.
3TC will be dosed as per standard guideline and routine practices.
Lopinavir is an antiretroviral of the protease inhibitor class. It is used against HIV infections as a fixed-dose combination with another protease inhibitor, ritonavir.
LPV/r will be dosed as per standard guideline and routine practices.
Other Name: Ritonavir-boosted lopinavir
- Percent of patients with initial viral suppression [ Time Frame: 24 weeks ]Suppression is defined as patients with plasma HIV RNA <50 copies/mL.
- Percent of patients maintaining viral suppression [ Time Frame: Between 24 and104 weeks ]Suppression is defined as patients with plasma HIV RNA <50 copies/mL.
- Prevalence of CD4 percentage greater than 30 [ Time Frame: By 24 weeks and sustained through 104 weeks ]Patients that reached a normal CD4% level.
- Prevalence of growth along curve within one standard deviation or upward trend [ Time Frame: Up to 104 weeks ]By comparing viral growth curves.
- Prevalence of detection of specific HIV antibody classes [ Time Frame: 24 and 104 weeks ]HIV antibody detection
- Size of the viral reservoir (copies/million cell) [ Time Frame: Up to 104 weeks ]Quantification of viral reservoir
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
|Ages Eligible for Study:||up to 48 Hours (Child)|
|Sexes Eligible for Study:||All|
|Accepts Healthy Volunteers:||No|
- Point of care (POC) or laboratory-based test positive on a sample collected within 48 hours of birth.
- Mother willing and able to provide informed consent.
- Expressed intention to leave the Johannesburg area permanently.
- Co-morbidities, birth defects or other conditions which in the opinion of the clinical team have a greater than 50% risk of mortality in the first days of life.
- Co-morbidities or conditions which in the opinion of the clinical team advise against initiation of ART within the first 48 hours of life.
- Active (uncontrolled) maternal psychiatric illness.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02431975
|Rahima Moosa Mother and Child Hospital|
|Johannesburg, Gauteng, South Africa|
|Principal Investigator:||Louise Kuhn, PhD||Columbia University|
|Responsible Party:||Louise Kuhn, Professor of Epidemiology, Department of Epidemiology, Columbia University|
|Other Study ID Numbers:||
U01HD080441 ( U.S. NIH Grant/Contract )
|First Posted:||May 1, 2015 Key Record Dates|
|Last Update Posted:||August 4, 2020|
|Last Verified:||July 2020|
|Individual Participant Data (IPD) Sharing Statement:|
|Plan to Share IPD:||Yes|
|Plan Description:||Contact PI Non-identifying data|
Statistical Analysis Plan (SAP)
Informed Consent Form (ICF)
Clinical Study Report (CSR)
|Time Frame:||Based on availability of resources|
|Access Criteria:||Scientific justification|
|Studies a U.S. FDA-regulated Drug Product:||No|
|Studies a U.S. FDA-regulated Device Product:||No|
|Product Manufactured in and Exported from the U.S.:||No|
antiretroviral therapy, highly active
HIV Protease Inhibitors
Viral Protease Inhibitors
Molecular Mechanisms of Pharmacological Action
Cytochrome P-450 CYP3A Inhibitors
Cytochrome P-450 Enzyme Inhibitors
Reverse Transcriptase Inhibitors
Nucleic Acid Synthesis Inhibitors
Cytochrome P-450 CYP3A Inducers
Cytochrome P-450 Enzyme Inducers